Palbociclib and INCMGA00012 in People With Advanced Liposarcoma

Summary

The researchers are doing this study to find out whether combining the study drugs palbociclib and INCMGA00012 is an effective and safe treatment for advanced liposarcoma. "Funding Source - FDA OOPD"

Timeline

Start

2020-06-17

Primary completion

2027-06

Completion

2027-06

Publications

• Rosenbaum E, Seier K, Gularte-Merida R, Seffar E, Dickson MA, Avutu V, Banks LB, Chan JE, Chi P, Gounder MM, Kelly CM, Keohan ML, Maki RG, Movva S, Reed D, Desir R, Biniakewitz M, Cho JM, Duchemin M, Erinjeri JP, Lefkowitz RA, Koff A, Singer S, Tap W, Qin LX, D'Angelo S. Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma. J Immunother Cancer. 2026 May 4;14(5):e014346. doi: 10.1136/jitc-2025-014346.
• Rosenbaum E, Gularte-Merida R, Seffar E, Lee J, Adamow M, Bradic M, Dickson MA, Avutu V, Banks LB, Chan JE, Chi P, Gounder MM, Kelly CM, Keohan ML, Maki RG, Movva S, Reed DR, Desir R, Biniakewitz M, Erinjeri JP, Lefkowitz RA, Wong P, Antonescu CR, Qin LX, Panageas KS, Shen R, Singer S, Koff A, Tap WD, D'Angelo SP. Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma. Cancer Res Commun. 2026 Feb 1;6(2):437-446. doi: 10.1158/2767-9764.CRC-25-0334.

Drugs

Indications